Home Articles Dapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure With Preserved Ejection Fraction: Insights From the Cardiac and Metabolic Effects of Dapagliflozin ...

Among patients with heart failure with preserved ejection fraction (HFpEF), lower versus higher ranges of EF signal fundamentally different morphologies and hemodynamic responses, which may have ...

In the realm of sports science, cardiovascular health represents a critical area of study, especially considering the ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Heart failure management includes the four pillars (quad therapy) in HFrEF and HFpEF, plus advances in heart transplantation ...

Some elite endurance athletes have evidence of impaired cardiac function, which, along with other findings, may raise suspicions of early dilated cardiomyopathy, according to results of a new study.

An overview of the PARAGON-HF trial with special consideration to the rationale behind the design, the cardiovascular end points, and the safety profile. John McMurray, MBChB: The most recent attempt ...

Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart ...

Jim Januzzi, MD, outlines a multitude of drug treatment options for heart failure revolving around patient ejection fraction (EF) status. Ryan Haumschild, PharmD, MS, MBA: As we start to transition ...

We read with great interest the research letter by Niemiec et al 1 on the use of sacubitril / valsartan in patients with pulmonary hypertension (PH) due to heart failure with preserved ejection ...